These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


253 related items for PubMed ID: 17492645

  • 1. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention.
    Mistry PK, Sadan S, Yang R, Yee J, Yang M.
    Am J Hematol; 2007 Aug; 82(8):697-701. PubMed ID: 17492645
    [Abstract] [Full Text] [Related]

  • 2. Gaucher's disease type I: a disease masked by the presence of abnormal laboratory tests common to primary liver disease.
    Saadi T, Rosenbaum H, Veitsman E, Baruch Y.
    Eur J Gastroenterol Hepatol; 2010 Aug; 22(8):1019-21. PubMed ID: 20093936
    [Abstract] [Full Text] [Related]

  • 3. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
    Piran S, Roberts A, Patterson MA, Amato D.
    Blood Cells Mol Dis; 2009 Aug; 43(3):289-93. PubMed ID: 19793665
    [Abstract] [Full Text] [Related]

  • 4. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
    Pastores GM, Elstein D, Hrebícek M, Zimran A.
    Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
    [Abstract] [Full Text] [Related]

  • 5. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J, Szücs FZ, Benkö K, Maródi L.
    Orv Hetil; 2003 Apr 20; 144(16):749-55. PubMed ID: 12778625
    [Abstract] [Full Text] [Related]

  • 6. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis.
    Kaplan P, Andersson HC, Kacena KA, Yee JD.
    Arch Pediatr Adolesc Med; 2006 Jun 20; 160(6):603-8. PubMed ID: 16754822
    [Abstract] [Full Text] [Related]

  • 7. Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study.
    Boomsma JM, van Dussen L, Wiersma MG, Groener JE, Aerts JM, Maas M, Hollak CE.
    Blood Cells Mol Dis; 2010 Mar 15; 44(3):181-7. PubMed ID: 20074983
    [Abstract] [Full Text] [Related]

  • 8. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
    Charrow J, Dulisse B, Grabowski GA, Weinreb NJ.
    Clin Genet; 2007 Mar 15; 71(3):205-11. PubMed ID: 17309642
    [Abstract] [Full Text] [Related]

  • 9. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G, Ponce E, Basack N, Freigeiro D, Aversa L, Graciela E, Kohan R.
    J Pediatr; 2007 Aug 15; 151(2):197-201. PubMed ID: 17643778
    [Abstract] [Full Text] [Related]

  • 10. [Diagnosis and treatment of Gaucher disease in Croatia].
    Mrsić M.
    Lijec Vjesn; 2007 May 15; 129 Suppl 3():38-42. PubMed ID: 18959062
    [Abstract] [Full Text] [Related]

  • 11. Disease state awareness in Gaucher disease: a Q&A expert roundtable discussion.
    Mistry PK, Weinthal JA, Weinreb NJ.
    Clin Adv Hematol Oncol; 2012 Jun 15; 10(6 Suppl 8):1-16. PubMed ID: 22895100
    [Abstract] [Full Text] [Related]

  • 12. Diagnosing Gaucher disease: an on-going need for increased awareness amongst haematologists.
    Thomas AS, Mehta AB, Hughes DA.
    Blood Cells Mol Dis; 2013 Mar 15; 50(3):212-7. PubMed ID: 23219328
    [Abstract] [Full Text] [Related]

  • 13. Miscellaneous non-inflammatory musculoskeletal conditions. Gaucher disease and bone.
    Mikosch P.
    Best Pract Res Clin Rheumatol; 2011 Oct 15; 25(5):665-81. PubMed ID: 22142746
    [Abstract] [Full Text] [Related]

  • 14. [Quality study of diagnostic and follow-up procedures of bone involvement in type 1 Gaucher"s disease in Spain].
    Pérez Calvo JI, Giraldo Castellano P, Rubio-Félix D, Giralt Reichs M, Pocoví Mieras M.
    An Med Interna; 2003 Dec 15; 20(12):607-11. PubMed ID: 14697079
    [Abstract] [Full Text] [Related]

  • 15. Early diagnosis of Gaucher disease in pediatric patients: proposal for a diagnostic algorithm.
    Di Rocco M, Andria G, Deodato F, Giona F, Micalizzi C, Pession A.
    Pediatr Blood Cancer; 2014 Nov 15; 61(11):1905-9. PubMed ID: 25131373
    [Abstract] [Full Text] [Related]

  • 16. Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations-implications for diagnosis and therapeutic monitoring.
    Grace ME, Balwani M, Nazarenko I, Prakash-Cheng A, Desnick RJ.
    Hum Mutat; 2007 Sep 15; 28(9):866-73. PubMed ID: 17464953
    [Abstract] [Full Text] [Related]

  • 17. Giant lymphadenopathy infiltrated by gaucher cells mimicking lymphoma.
    Yağci B, Salor O, Yalçin B, Gürakan F, Güçer S, Büyükpamukçu M.
    Pediatr Blood Cancer; 2009 Jul 15; 52(7):870-1. PubMed ID: 19213078
    [Abstract] [Full Text] [Related]

  • 18. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians.
    Mehta A, Belmatoug N, Bembi B, Deegan P, Elstein D, Göker-Alpan Ö, Lukina E, Mengel E, Nakamura K, Pastores GM, Pérez-López J, Schwartz I, Serratrice C, Szer J, Zimran A, Di Rocco M, Panahloo Z, Kuter DJ, Hughes D.
    Mol Genet Metab; 2017 Nov 15; 122(3):122-129. PubMed ID: 28847676
    [Abstract] [Full Text] [Related]

  • 19. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
    Hollak CE, van Weely S, van Oers MH, Aerts JM.
    J Clin Invest; 1994 Mar 15; 93(3):1288-92. PubMed ID: 8132768
    [Abstract] [Full Text] [Related]

  • 20. Phenotypic and genotypic heterogeneity in Gaucher disease type 1: a comparison between Brazil and the rest of the world.
    Sobreira E, Pires RF, Cizmarik M, Grabowski GA.
    Mol Genet Metab; 2007 Jan 15; 90(1):81-6. PubMed ID: 16996765
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 13.